Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Exploring Cholinergic Changes and their Associations with Sleep Alterations in the Lewy Body Disease Spectrum: New Biomarkers and Therapeutic Targets

Award Number: K99NS146570
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 02/16/2026
PERIOD OF PERFORMANCE END DATE: 01/31/2028

Group Awards By:

View Award Description

Exploring Cholinergic Changes and their Associations with Sleep Alterations in the Lewy Body Disease Spectrum: New Biomarkers and Therapeutic Targets - Abstract Cholinergic brain activity plays a crucial role in regulating sleep, particularly Rapid Eye Movement (REM) sleep, as demonstrated in animal studies. How these findings translate to humans remains insufficiently explored. Understanding the neurobiology of sleep in humans is critical, as sleep dysregulation is closely linked to neurodegeneration, making sleep a promising therapeutic target. REM sleep behavior disorder (RBD), an early sign of Parkinson’s disease (PD) and Dementia with Lewy Bodies—collectively known as Lewy Body Disorders (LBD) —often appears decades before diagnosis, where it is referred to as isolated RBD. Cholinergic changes also emerge early in LBD, possibly starting in isolated RBD phase. These changes extend beyond the typical decline in cholinergic activity and can include compensatory mechanisms, such as increased activity of the vesicular acetylcholine transporter. We hypothesize that changes in cholinergic neurotransmission, whether increases or decreases, can affect the tonic and phasic availability of acetylcholine. Changes in tonic and phasic availability of acetylcholine, in turn, may disrupt the sleep-wake cycle, leading to REM sleep disturbances such as RBD among others. Our preliminary findings in patients with PD support this hypothesis. We observed cholinergic changes using the selective brain PET radiotracer [18F]-FEOBV, which binds to the vesicular acetylcholine transporter, and self-reported measures of RBD symptoms and excessive daytime sleepiness. Wearable at-home sleep recording devices, such as the Sleep Profiler™, provide a patient-friendly method for quantifying sleep architecture and its alterations with performance comparable to traditional in-lab polysomnography. These technologies enable more ecological investigations of sleep biomarkers. The main aim of this study is to investigate the relationship between cholinergic brain changes and sleep, moving beyond qualitative, questionnaire-based measures in patients with PD (K99) and isolated RBD (R00). We will do that by using advanced imaging techniques ([18F]-FEOBV PET) and wearable sleep recording devices (Sleep Profiler™). During the K99 phase, we will focus on patients with PD, examining the association between cholinergic changes and REM (Aim 1) and non-REM sleep alterations (Aim 2). Building on the skills acquired during the K99 (sleep recording analyses and neurobiology of sleep), I will transition to the independent R00 phase to investigate cholinergic changes in a newly recruited cohort of patients with isolated RBD. I will explore how these changes relate to sleep architecture and clinical progression (one-year follow-up). This research can provide valuable insights into how the cholinergic system contributes to sleep disturbances, potentially paving the way for novel cholinergic modulation treatments that target sleep to protect brain health in isolated RBD and LBD. It may also validate the use of wearable sleep devices for at-home monitoring of cholinergic system changes. The findings in this study will inform the design of future research on molecular mechanisms linked to sleep disturbances and neurodegeneration.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $128,358 )
2026	2026	REGENTS OF THE UNIVERSITY OF MICHIGAN	1109 GEDDES AVE STE 3300	ANN ARBOR	MI	48109	WASHTENAW	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	2/16/2026	NEW	$128,358
														Subtotal = $128,358

Grand Total All Awards = $128,358

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Exploring Cholinergic Changes and their Associations with Sleep Alterations in the Lewy Body Disease Spectrum: New Biomarkers and Therapeutic Targets

Award Number: K99NS146570

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 02/16/2026

PERIOD OF PERFORMANCE END DATE: 01/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer